VALN — Valneva SE

Valneva (VALN) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenues: EUR 30.9 million, down from EUR 49.2 million in Q1 2025.
• Product Sales: EUR 30.5 million, compared to EUR 48.6 million a year ago.
  • IXIARO Sales: EUR 20.2 million (down from EUR 27.5 million).
  • DUKORAL Sales: EUR 8.6 million (down from EUR 12.3 million).
  • IXCHIQ Sales: EUR 1.6 million (down from EUR 3 million).
• Operating Loss: EUR 23.7 million, compared to a loss of EUR 9.2 million in Q1 2025.
• Net Loss: EUR 32.1 million, influenced by a foreign exchange loss of EUR 3 million.
• Cash Position: EUR 105 million at the end of March 2026, down from EUR 110 million at the end of 2025.

2. Strategic Updates and Business Highlights:

• Lyme Vaccine (VLA15): Phase III trial showed strong efficacy (>70%) but did not meet the first prespecified statistical criteria. Pfizer plans regulatory submissions based on the second criteria meeting.
• Chikungunya Vaccine (IXCHIQ): Ongoing pilot vaccination campaign in Brazil, aiming for 20%-40% coverage in targeted populations.
• Shigella Vaccine: Advanced tetravalent candidate with ongoing studies in Africa; results expected in summer 2026.
• Restructuring Plan: Aims to reduce operating expenses by 25%-35% and workforce by 10%-15% to enhance cash management.

3. Forward Guidance and Outlook:

• Revised Sales Guidance: Product sales expected to be between EUR 135 million and EUR 150 million for FY 2026, with total revenues projected at EUR 145 million to EUR 160 million, reflecting a cautious outlook due to geopolitical factors affecting travel vaccine uptake.
• Cash Management Focus: Emphasis on cash containment and management amid uncertainties surrounding the Lyme vaccine.

4. Bad News, Challenges, or Points of Concern:

• Declining Sales: Significant year-over-year declines in product sales, particularly for IXIARO and DUKORAL, primarily due to phasing of deliveries and changes in distribution partnerships.
• Increased Costs: Higher cost of goods sold due to idle capacity and manufacturing issues, leading to a gross margin drop (45.2% in Q1 2026 vs. 62.7% in Q1 2025).
• Regulatory Uncertainty: Ongoing concerns regarding the FDA's pre-approval process for the Almeida manufacturing facility, which could impact IXIARO sales.
• Travel Market Slowdown: Observed decline in travel impacting vaccine uptake, with potential further downside risks depending on geopolitical developments.

5. Notable Q&A Insights:

• Lyme Vaccine Data Release: Pfizer is preparing to present full clinical data at an upcoming conference, though no specific date has been confirmed.
• FDA Discussions: Valneva is not directly involved in Pfizer's discussions with the FDA but is kept informed through established processes.
• Restructuring Impact: Savings from the restructuring plan will primarily come from R&D, with full payback expected next year due to legal processes in Austria.
• Market Dynamics: Management acknowledged the potential for further revenue declines if geopolitical tensions worsen, impacting travel and vaccine sales.

Overall, Valneva is navigating significant challenges in sales and operational costs while focusing on strategic initiatives in vaccine development and cash management. The outlook remains cautious amid external market pressures and regulatory uncertainties.